Abstract
Combining the specificity and stability of antibodies with the potency of small molecules has always been at the core of the antibody-drug conjugate (ADC) field. The technological challenge to this therapeutic approach is in bringing two disparate molecules in union with one another. Once this was achieved, the next technological hurdle was, in essence, automation (1).

Early versions of an ADC were the product of technical skill which also required trial and error. Bioconjugation experts investigated many combinations of antibodies, small molecule drugs, conditions, and reaction times to produce stable and efficacious final drugs. This work serves as a technical knowledge base from which to convert new antibodies into ADCs. Even with compendium textbooks like Bioconjugate Techniques, trial and error is still required especially to manufacture an ADC at clinical scale.

Read Full Article

 

Advertisement #3
Lonza White Paper 2023
Axplora
Information March 22-720x90-1.png
 

Authors:

Corresponding Authors: Derrick Houser. E-mail: Derrick Houser  and Scott Beaver, Ph.D. E-mail: Scott Beaver, Ph.D.

Key terms: ADC, bioconjugation, automation, bioconjugation techniques
Published In: ADC Review| Journal of Antibody-drug Conjugates

DOI: https://doi.org/10.14229/jadc.2023.04.10.001.

How to cite:
Houser D. 1 and Beaver S. 1 2 Automating ADC Manufacturing with Electricity – J. ADC. April 10, 2023. DOI: 10.14229/jadc.2023.04.10.001.

1 Express biolabs
2 ChemTalk

Last Editorial Review: March 31, 2023

Creative Commons License

Article History:

  • Original Manuscript Received January 24, 2023
  • Review results received March 23, 2022
  • Manuscript accepted for publication April  10, 2023
Lonza White Paper 2023
Advertisement #4
Previous articleAccelerating the Development of Differentiated ADCs: BioNTech and DualityBio Form Global Strategic Partnership
Next articleA Preclinical Profile of the Potential of BYON3521
Avatar photo
Derrick Houser
Derrick Houser is an industry professional with over 14 years of experience in biotechnology drug discovery and development specifically in the antibody and cell therapy fields. His undergrad training in chemistry was followed by industry training in biology and biochemistry all of which was supplemented with a personal interest in physics, electrochemistry, and engineering. A self-starter by nature, he spent his nights and weekends renting lab space in the San Francisco Bay area to apply his years of training on his own scientific ideas while working as a full time scientist by day. This work led to multiple entrepreneurial ventures and laid the foundation for Express Biolabs.
Scott Beaver, Ph.D.
Scott Beaver, Ph.D., or “Dr Scott,” has a doctorate degree in chemical engineering from the University of California. He makes fun, approachable college prep courses for homeschoolers, home educators, and teachers in four continents and most English-speaking countries. Dr Scott has created video textbooks for chemistry and math. They are based on his experiences as a college professor, where he learned exactly what one needs to know to succeed in higher education. He’s been teaching and working with homeschool groups for decades. He received teaching training as a Fellow of the National Science Foundation (NSF). He is an expert at connecting with learners interested in science. Previously, Dr Scott provided regulatory guidance and consulting services to corporations and governments for preserving and improving environmental quality. He also founded several startups in the chemicals industry. Recently, he has been traveling and enjoying life while spreading his message that you, too, can find your path using online learning, anywhere, any time. Dr Scott has recently joined the Board of Advisors for ChemTalk, a nonprofit dedicated to making chemistry fun, and Express BioLabs